Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Liver Diseases

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    April 2018
  1. YI SW, Choi JS, Yi JJ, Lee YH, et al
    Risk factors for hepatocellular carcinoma by age, sex, and liver disorder status: A prospective cohort study in Korea.
    Cancer. 2018 Apr 18. doi: 10.1002/cncr.31406.
    PubMed     Text format     Abstract available


  2. ERSTAD DJ, Fuchs BC, Tanabe KK
    Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy.
    Cancer. 2018 Apr 17. doi: 10.1002/cncr.31257.
    PubMed     Text format     Abstract available


  3. CHINO F, Stephens SJ, Choi SS, Marin D, et al
    The role of external beam radiotherapy in the treatment of hepatocellular cancer.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31334.
    PubMed     Text format     Abstract available


  4. KIM NG, Nguyen PP, Dang H, Kumari R, et al
    Temporal trends in disease presentation and survival of patients with hepatocellular carcinoma: A real-world experience from 1998 to 2015.
    Cancer. 2018 Apr 6. doi: 10.1002/cncr.31373.
    PubMed     Text format     Abstract available


    March 2018
  5. COSTENTIN CE, Mourad A, Lahmek P, Causse X, et al
    Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study.
    Cancer. 2018 Mar 28. doi: 10.1002/cncr.31215.
    PubMed     Text format     Abstract available


  6. ZHAI XF, Liu XL, Shen F, Fan J, et al
    Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.30915.
    PubMed     Text format     Abstract available


    February 2018
  7. KIM HS, Shaib WL, Zhang C, Nagaraju GP, et al
    Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Cancer. 2018 Feb 16. doi: 10.1002/cncr.31192.
    PubMed     Text format     Abstract available


    January 2018
  8. NEUWIRTH MG, Bierema C, Sinnamon AJ, Fraker DL, et al
    Trends in major upper abdominal surgery for cancer in octogenarians: Has there been a change in patient selection?
    Cancer. 2018;124:125-135.
    PubMed     Text format     Abstract available


    December 2017
  9. MOMIN BR, Pinheiro PS, Carreira H, Li C, et al
    Liver cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5059-5078.
    PubMed     Text format     Abstract available


    October 2017
  10. MOKDAD AA, Murphy CC, Pruitt SL, Mansour JC, et al
    Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinoma.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31066.
    PubMed     Text format     Abstract available


    August 2017
  11. TRAN CAO HS, Zhang Q, Sada YH, Chai C, et al
    The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts.
    Cancer. 2017 Aug 25. doi: 10.1002/cncr.30968.
    PubMed     Text format     Abstract available


  12. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available


  13. HUNG YP, Lovitch SB, Qian X
    Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics.
    Cancer. 2017;125:604-614.
    PubMed     Text format     Abstract available


    July 2017
  14. LEWIS DR, Chen HS, Cockburn MG, Wu XC, et al
    Early estimates of SEER cancer incidence, 2014.
    Cancer. 2017;123:2524-2534.
    PubMed     Text format     Abstract available


    June 2017
  15. KASUYA G, Kato H, Yasuda S, Tsuji H, et al
    Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: Combined analyses of 2 prospective trials.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30816.
    PubMed     Text format     Abstract available


  16. LIN YY, Yu MW, Lin SM, Lee SD, et al
    Genome-wide association analysis identifies a GLUL haplotype for familial hepatitis B virus-related hepatocellular carcinoma.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30851.
    PubMed     Text format     Abstract available


  17. PARIKH ND, Singal AG, Hutton DW
    Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30863.
    PubMed     Text format     Abstract available


  18. CHAN SL, Yeo W, Mo F, Chan AWH, et al
    A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30825.
    PubMed     Text format     Abstract available


  19. KIM Y, Lee SJ, Lee JY, Lee SH, et al
    Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
    Cancer. 2017;123:1958-1964.
    PubMed     Text format     Abstract available


    May 2017
  20. TARHINI AA, Rafique I, Floros T, Tran P, et al
    Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30717.
    PubMed     Text format     Abstract available


    April 2017
  21. ZHOU H, Guo M, Gong Y
    Challenge of FNA diagnosis of angiomyolipoma: A study of 33 cases.
    Cancer. 2017;125:257-266.
    PubMed     Text format     Abstract available


    February 2017
  22. HUANG J, Fogg M, Wirth LJ, Daley H, et al
    Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Cancer. 2017 Feb 21. doi: 10.1002/cncr.30541.
    PubMed     Text format     Abstract available


  23. KATZENSTEIN HM, Furman WL, Malogolowkin MH, Krailo MD, et al
    Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee.
    Cancer. 2017 Feb 17. doi: 10.1002/cncr.30591.
    PubMed     Text format     Abstract available


  24. FRANKEL TL, Vakiani E, Nathan H, DeMatteo RP, et al
    Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
    Cancer. 2017;123:568-575.
    PubMed     Text format     Abstract available


  25. SAHLMANN CO, Homayounfar K, Niessner M, Dyczkowski J, et al
    Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long-term efficacy results of a prospective phase 2 study.
    Cancer. 2017;123:638-649.
    PubMed     Text format     Abstract available


  26. REDDY SK, Boland PM, Nurkin SJ
    Primary tumor resection does not improve survival among patients with unresectable colorectal cancer metastases-But who determines resectability?
    Cancer. 2017 Feb 8. doi: 10.1002/cncr.30595.
    PubMed     Text format    


    January 2017
  27. MANCUSO A
    Management of hepatocellular carcinoma in thalassemia and importance of the human factor.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30551.
    PubMed     Text format    


  28. MOUKHADDER HM, Halawi R, Cappellini MD, Taher AT, et al
    Reply to Management of hepatocellular carcinoma in thalassemia and importance of the human factor.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30550.
    PubMed     Text format    


  29. KUTLU OC, Chan JA, Aloia TA, Chun YS, et al
    Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30531.
    PubMed     Text format     Abstract available


  30. LAMARCA A, Pihlak R, Frizziero M, McNamara MG, et al
    Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection.
    Cancer. 2017 Jan 6. doi: 10.1002/cncr.30502.
    PubMed     Text format    


  31. MARMOR S, Burke EE, Virnig BA, Jensen EH, et al
    Reply to Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection.
    Cancer. 2017 Jan 6. doi: 10.1002/cncr.30500.
    PubMed     Text format    


  32. PRINTZ C
    Cancer mortality rates vary among specific Asian American ethnic groups.
    Cancer. 2017;123:11.
    PubMed     Text format    


    December 2016
  33. YAMASHITA S, Koay EJ, Passot G, Shroff R, et al
    Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients.
    Cancer. 2016 Dec 16. doi: 10.1002/cncr.30488.
    PubMed     Text format     Abstract available


  34. MOUKHADDER HM, Halawi R, Cappellini MD, Taher AT, et al
    Hepatocellular carcinoma as an emerging morbidity in the thalassemia syndromes: A comprehensive review.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30462.
    PubMed     Text format     Abstract available


    October 2016
  35. PONZETTO A, Figura N
    High hepatocellular carcinoma risk among US-born Hispanics.
    Cancer. 2016 Oct 14. doi: 10.1002/cncr.30397.
    PubMed     Text format    


  36. SETIAWAN VW, Wei PC, Hernandez BY, Lu SC, et al
    Reply to high hepatocellular carcinoma risk among US-born Hispanics.
    Cancer. 2016 Oct 14. doi: 10.1002/cncr.30396.
    PubMed     Text format    


    September 2016
  37. LORIOT Y, Fizazi K, de Bono JS, Forer D, et al
    Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
    Cancer. 2016 Sep 20. doi: 10.1002/cncr.30336.
    PubMed     Text format     Abstract available


  38. CHOO SP, Tan WL, Goh BK, Tai WM, et al
    Comparison of hepatocellular carcinoma in Eastern versus Western populations.
    Cancer. 2016 Sep 13. doi: 10.1002/cncr.30237.
    PubMed     Text format     Abstract available


    August 2016
  39. YANG JD, Altekruse SF, Nguyen MH, Gores GJ, et al
    Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States.
    Cancer. 2016 Aug 29. doi: 10.1002/cncr.30246.
    PubMed     Text format     Abstract available


  40. SHOUSHTARI AN, Munhoz RR, Kuk D, Ott PA, et al
    The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
    Cancer. 2016 Aug 17. doi: 10.1002/cncr.30259.
    PubMed     Text format     Abstract available


    July 2016
  41. CRANE CH, Koay EJ
    Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance.
    Cancer. 2016;122:1974-86.
    PubMed     Text format     Abstract available


    June 2016
  42. DROOGER JC, van Tinteren H, de Groot SM, Ten Tije AJ, et al
    A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30141.
    PubMed     Text format     Abstract available


    May 2016
  43. SINGAL AG, Yopp AC
    Hepatocellular carcinoma: How can we move from racial/ethnic disparities to a model of health equity?
    Cancer. 2016 May 19. doi: 10.1002/cncr.30099.
    PubMed     Text format    


  44. HA J, Yan M, Aguilar M, Bhuket T, et al
    Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States.
    Cancer. 2016 May 19. doi: 10.1002/cncr.30103.
    PubMed     Text format     Abstract available


  45. NAKAMURA T, Matsumine A, Kawai A, Araki N, et al
    The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Cancer. 2016;122:1408-16.
    PubMed     Text format     Abstract available


    April 2016
  46. TAKEDA A, Sanuki N, Tsurugai Y, Iwabuchi S, et al
    Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.
    Cancer. 2016 Apr 8. doi: 10.1002/cncr.30008.
    PubMed     Text format     Abstract available


    March 2016
  47. MAKAROVA-RUSHER OV, Altekruse SF, McNeel TS, Ulahannan S, et al
    Population attributable fractions of risk factors for hepatocellular carcinoma in the United States.
    Cancer. 2016 Mar 21. doi: 10.1002/cncr.29971.
    PubMed     Text format     Abstract available


  48. RYERSON AB, Eheman CR, Altekruse SF, Ward JW, et al
    Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.
    Cancer. 2016 Mar 9. doi: 10.1002/cncr.29936.
    PubMed     Text format     Abstract available


  49. MOR V, Joyce NR, Cote DL, Gidwani RA, et al
    The rise of concurrent care for veterans with advanced cancer at the end of life.
    Cancer. 2016;122:782-90.
    PubMed     Text format     Abstract available


    February 2016
  50. DEPERALTA DK, Wei L, Ghoshal S, Schmidt B, et al
    Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.
    Cancer. 2016 Feb 23. doi: 10.1002/cncr.29912.
    PubMed     Text format     Abstract available


    January 2016
  51. ESNAOLA NF, Meyer JE, Karachristos A, Maranki JL, et al
    Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma.
    Cancer. 2016 Jan 22. doi: 10.1002/cncr.29692.
    PubMed     Text format     Abstract available


    December 2015
  52. TAPPER EB, Catana AM, Sethi N, Mansuri D, et al
    Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis.
    Cancer. 2015 Dec 30. doi: 10.1002/cncr.29855.
    PubMed     Text format     Abstract available


  53. KONSTANTINIDIS IT, Koerkamp BG, Do RK, Gonen M, et al
    Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
    Cancer. 2015 Dec 22. doi: 10.1002/cncr.29824.
    PubMed     Text format     Abstract available


  54. STEUER CE, Behera M, Berry L, Kim S, et al
    Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
    Cancer. 2015 Dec 22. doi: 10.1002/cncr.29812.
    PubMed     Text format     Abstract available


    October 2015
  55. MARTIN RC 2ND, Scoggins CR, Schreeder M, Rilling WS, et al
    Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Cancer. 2015;121:3649-58.
    PubMed     Text format     Abstract available


    September 2015
  56. BISHOP AJ, Ensor J, Moulder SL, Shaitelman SF, et al
    Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy.
    Cancer. 2015 Sep 8. doi: 10.1002/cncr.29681.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: